FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2070824050> ?p ?o ?g. }

• W2070824050 endingPage "74" @default.
• W2070824050 startingPage "63" @default.
• W2070824050 abstract "Since the early 1990s, three consecutive pediatric acute myeloid leukemia (AML) trials have been performed in Austria (AML-Berlin-Frankfurt-Münster (BFM) 93, AML-BFM 98, and AML-BFM 2004) in close cooperation with the international BFM study center. Herein, we review the pertinent patient characteristics, therapy, and outcome data.From January 1993 to April 2013, 249 children and adolescents (193 protocol patients) diagnosed with AML were enrolled in the three BFM studies. Patients were mainly treated in one of five pediatric hematology/oncology centers distributed over Austria.Many characteristics and outcome parameters were not statistically different between the three trials. Almost similar proportions of patients were stratified into two risk groups: standard risk (SR) (approximately 37 % overall) and high-risk (HR) (61 %). MLL rearrangements were found in 23 % of patients overall as the most frequent genetic aberration subtype. Complete remission (CR) was achieved by 84-95 % of patients. The most important type of event was leukemic relapse (5-year cumulative incidence 40 ± 8 %, 21 ± 5 %, and 39 ± 6 %; p = 0.058), with a trend to a higher rate specifically in SR patients of study AML-BFM 2004 compared with AML-BFM 98. Importantly, the frequency of death from causes other than relapse sequelae declined over the years (AML-BFM 93: 5/42 12 %, AML-BFM 98: 5/57 9 %, and AML-BFM 2004: 5/94 5 %). Altogether, event-free survival at 5 years varied insignificantly (48 ± 8 %, 61 ± 7 %, and 50 ± 6 %; p = 0.406). Nevertheless, survival (pSU) apparently improved from BFM 93 to subsequent studies, both overall (57 ± 8 %, 75 ± 6 %, and 62 ± 6 %; p = 0.046) and regarding the HR group (5-year-probability of survival (pSU) 40 ± 10 %, 66 ± 8 %, and 52 ± 8 %; p = 0.039).Treatment of pediatric AML in Austria renders survival rates in the range of international best practice. However, unambiguous statistical comparison of treatment periods is eventually hampered by small numbers and inequalities of recruitment. Hence, only internationally collaborative trials will allow developing treatment further to achieve higher cure rates with fewer events." @default.
• W2070824050 created "2016-06-24" @default.
• W2070824050 creator A5000105491 @default.
• W2070824050 creator A5002788784 @default.
• W2070824050 creator A5012680652 @default.
• W2070824050 creator A5015761988 @default.
• W2070824050 creator A5019136202 @default.
• W2070824050 creator A5020380214 @default.
• W2070824050 creator A5032193828 @default.
• W2070824050 creator A5034989366 @default.
• W2070824050 creator A5042206697 @default.
• W2070824050 creator A5046857875 @default.
• W2070824050 creator A5050618776 @default.
• W2070824050 creator A5062188329 @default.
• W2070824050 creator A5064325786 @default.
• W2070824050 creator A5072905145 @default.
• W2070824050 creator A5084599424 @default.
• W2070824050 creator A5087860986 @default.
• W2070824050 date "2014-02-01" @default.
• W2070824050 modified "2023-09-27" @default.
• W2070824050 title "Development of treatment and clinical results in childhood AML in Austria (1993–2013)" @default.
• W2070824050 cites W1784548805 @default.
• W2070824050 cites W1977985381 @default.
• W2070824050 cites W1979699800 @default.
• W2070824050 cites W1981347116 @default.
• W2070824050 cites W1993151769 @default.
• W2070824050 cites W1999940765 @default.
• W2070824050 cites W2006940777 @default.
• W2070824050 cites W2011967482 @default.
• W2070824050 cites W2016694142 @default.
• W2070824050 cites W2021663709 @default.
• W2070824050 cites W2021982292 @default.
• W2070824050 cites W2033039774 @default.
• W2070824050 cites W2040336044 @default.
• W2070824050 cites W2042649741 @default.
• W2070824050 cites W2046764865 @default.
• W2070824050 cites W2052100514 @default.
• W2070824050 cites W2052257391 @default.
• W2070824050 cites W2064575538 @default.
• W2070824050 cites W2066190791 @default.
• W2070824050 cites W2073140442 @default.
• W2070824050 cites W2077031414 @default.
• W2070824050 cites W2080444540 @default.
• W2070824050 cites W2083674935 @default.
• W2070824050 cites W2087823195 @default.
• W2070824050 cites W2107398329 @default.
• W2070824050 cites W2108300554 @default.
• W2070824050 cites W2120279462 @default.
• W2070824050 cites W2121565126 @default.
• W2070824050 cites W2129338773 @default.
• W2070824050 cites W2131713200 @default.
• W2070824050 cites W2133432816 @default.
• W2070824050 cites W2159289068 @default.
• W2070824050 cites W2163358530 @default.
• W2070824050 cites W2313645169 @default.
• W2070824050 cites W2317674375 @default.
• W2070824050 cites W2332175111 @default.
• W2070824050 cites W2893539009 @default.
• W2070824050 cites W2977606681 @default.
• W2070824050 doi "https://doi.org/10.1007/s12254-014-0135-y" @default.
• W2070824050 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7102234" @default.
• W2070824050 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32288851" @default.
• W2070824050 hasPublicationYear "2014" @default.
• W2070824050 type Work @default.
• W2070824050 sameAs 2070824050 @default.
• W2070824050 citedByCount "4" @default.
• W2070824050 countsByYear W20708240502014 @default.
• W2070824050 countsByYear W20708240502019 @default.
• W2070824050 countsByYear W20708240502021 @default.
• W2070824050 countsByYear W20708240502023 @default.
• W2070824050 crossrefType "journal-article" @default.
• W2070824050 hasAuthorship W2070824050A5000105491 @default.
• W2070824050 hasAuthorship W2070824050A5002788784 @default.
• W2070824050 hasAuthorship W2070824050A5012680652 @default.
• W2070824050 hasAuthorship W2070824050A5015761988 @default.
• W2070824050 hasAuthorship W2070824050A5019136202 @default.
• W2070824050 hasAuthorship W2070824050A5020380214 @default.
• W2070824050 hasAuthorship W2070824050A5032193828 @default.
• W2070824050 hasAuthorship W2070824050A5034989366 @default.
• W2070824050 hasAuthorship W2070824050A5042206697 @default.
• W2070824050 hasAuthorship W2070824050A5046857875 @default.
• W2070824050 hasAuthorship W2070824050A5050618776 @default.
• W2070824050 hasAuthorship W2070824050A5062188329 @default.
• W2070824050 hasAuthorship W2070824050A5064325786 @default.
• W2070824050 hasAuthorship W2070824050A5072905145 @default.
• W2070824050 hasAuthorship W2070824050A5084599424 @default.
• W2070824050 hasAuthorship W2070824050A5087860986 @default.
• W2070824050 hasBestOaLocation W20708240502 @default.
• W2070824050 hasConcept C120665830 @default.
• W2070824050 hasConcept C121332964 @default.
• W2070824050 hasConcept C126322002 @default.
• W2070824050 hasConcept C187212893 @default.
• W2070824050 hasConcept C194409129 @default.
• W2070824050 hasConcept C2778729363 @default.
• W2070824050 hasConcept C61511704 @default.
• W2070824050 hasConcept C71924100 @default.
• W2070824050 hasConcept C72563966 @default.
• W2070824050 hasConcept C88879693 @default.

• next